READING, Pa.– SAI MedPartners (“SAI”), a global consultancy providing strategic insights and analytics to the pharmaceutical, biotechnology, and medical device industries, is pleased to announce that it has acquired IDEA Pharma (“IDEA”). Northlane Capital Partners (“NCP”) partnered with management to acquire SAI in June 2022.
IDEA, headquartered in London, United Kingdom, specializes in pharmaceutical path-to-market strategy and innovation. This acquisition strengthens SAI’s capacity to offer comprehensive strategic services to its biopharma clients, supporting the process from drug discovery to market launch and lifecycle management.
Integrating IDEA’s expertise in early-phase positioning, clinical development, and commercialization with SAI’s extensive knowledge and expertise in competitive intelligence, market research, and market access consulting services will create a unique value proposition for biopharma clients. The collaboration will provide clients with an unmatched blend of market foresight, strategic creativity, and decision-support services to help develop and launch more great medicines.
Erik Nordhoy, CEO of SAI, commented, “The addition of IDEA to the SAI organization brings incredible management talent and demonstrated thought leadership regarding strategic positioning and commercialization of new therapies. The strategic fit with our existing service offerings materially enhances our ability to serve as a key partner to our clients.”
Mike Rea, Founder and CEO of IDEA, added, “We are excited to join forces with SAI. Together, we will be better positioned to drive real innovation and impact for patients worldwide.”
